431 related articles for article (PubMed ID: 33510643)
21. The Role of Primary Motor Cortex (M1) Glutamate and GABA Signaling in l-DOPA-Induced Dyskinesia in Parkinsonian Rats.
Lindenbach D; Conti MM; Ostock CY; George JA; Goldenberg AA; Melikhov-Sosin M; Nuss EE; Bishop C
J Neurosci; 2016 Sep; 36(38):9873-87. PubMed ID: 27656025
[TBL] [Abstract][Full Text] [Related]
22. Effects of hydrogen gas inhalation on L-DOPA-induced dyskinesia.
Nascimento GC; Santos BM; Pedrazzi JF; Silva-Amaral D; Bortolanza M; Harris GT; Del Bel E; Branco LGS
Brain Behav Immun Health; 2023 Jul; 30():100623. PubMed ID: 37096172
[TBL] [Abstract][Full Text] [Related]
23. Striatal overexpression of β-arrestin2 counteracts L-dopa-induced dyskinesia in 6-hydroxydopamine lesioned Parkinson's disease rats.
Zhang ZR; Zhang XR; Luan XQ; Wang XS; Wang WW; Wang XY; Shao B; Xie CL
Neurochem Int; 2019 Dec; 131():104543. PubMed ID: 31491493
[TBL] [Abstract][Full Text] [Related]
24. RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease.
Ko WK; Martin-Negrier ML; Bezard E; Crossman AR; Ravenscroft P
Neurobiol Dis; 2014 Oct; 70():138-48. PubMed ID: 24969021
[TBL] [Abstract][Full Text] [Related]
25. The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.
Frau R; Savoia P; Fanni S; Fiorentini C; Fidalgo C; Tronci E; Stancampiano R; Meloni M; Cannas A; Marrosu F; Bortolato M; Devoto P; Missale C; Carta M
Exp Neurol; 2017 May; 291():1-7. PubMed ID: 28131725
[TBL] [Abstract][Full Text] [Related]
26. Acupuncture Alleviates Levodopa-Induced Dyskinesia via Melanin-Concentrating Hormone in Pitx3-Deficient aphakia and 6-Hydroxydopamine-Lesioned Mice.
Kim YK; Lee AR; Park H; Yoo J; Ahn S; Jeon SH; Kim J; Park HJ
Mol Neurobiol; 2019 Apr; 56(4):2408-2423. PubMed ID: 30030752
[TBL] [Abstract][Full Text] [Related]
27. Genetic deletion of GPR88 enhances the locomotor response to L-DOPA in experimental parkinsonism while counteracting the induction of dyskinesia.
Mantas I; Yang Y; Mannoury-la-Cour C; Millan MJ; Zhang X; Svenningsson P
Neuropharmacology; 2020 Jan; 162():107829. PubMed ID: 31666199
[TBL] [Abstract][Full Text] [Related]
28. Striatal Nurr1 Facilitates the Dyskinetic State and Exacerbates Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease.
Sellnow RC; Steece-Collier K; Altwal F; Sandoval IM; Kordower JH; Collier TJ; Sortwell CE; West AR; Manfredsson FP
J Neurosci; 2020 Apr; 40(18):3675-3691. PubMed ID: 32238479
[TBL] [Abstract][Full Text] [Related]
29. Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
Kobylecki C; Cenci MA; Crossman AR; Ravenscroft P
J Neurochem; 2010 Jul; 114(2):499-511. PubMed ID: 20456008
[TBL] [Abstract][Full Text] [Related]
30. 5alpha-reductase inhibitors dampen L-DOPA-induced dyskinesia via normalization of dopamine D1-receptor signaling pathway and D1-D3 receptor interaction.
Fanni S; Scheggi S; Rossi F; Tronci E; Traccis F; Stancampiano R; De Montis MG; Devoto P; Gambarana C; Bortolato M; Frau R; Carta M
Neurobiol Dis; 2019 Jan; 121():120-130. PubMed ID: 30261284
[TBL] [Abstract][Full Text] [Related]
31. Regulation of dopamine neurotransmission from serotonergic neurons by ectopic expression of the dopamine D2 autoreceptor blocks levodopa-induced dyskinesia.
Sellnow RC; Newman JH; Chambers N; West AR; Steece-Collier K; Sandoval IM; Benskey MJ; Bishop C; Manfredsson FP
Acta Neuropathol Commun; 2019 Jan; 7(1):8. PubMed ID: 30646956
[TBL] [Abstract][Full Text] [Related]
32. Late aging-associated increases in L-DOPA-induced dyskinesia are accompanied by heightened neuroinflammation in the hemi-parkinsonian rat.
Lanza K; Perkins AE; Deak T; Bishop C
Neurobiol Aging; 2019 Sep; 81():190-199. PubMed ID: 31306813
[TBL] [Abstract][Full Text] [Related]
33. mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias.
Morin N; Morissette M; Grégoire L; Di Paolo T
Curr Neuropharmacol; 2016; 14(5):481-93. PubMed ID: 26639458
[TBL] [Abstract][Full Text] [Related]
34. Effects of prolonged neuronal nitric oxide synthase inhibition on the development and expression of L-DOPA-induced dyskinesia in 6-OHDA-lesioned rats.
Padovan-Neto FE; Cavalcanti-Kiwiatkoviski R; Carolino RO; Anselmo-Franci J; Del Bel E
Neuropharmacology; 2015 Feb; 89():87-99. PubMed ID: 25196732
[TBL] [Abstract][Full Text] [Related]
35. Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia.
Bézard E; Muñoz A; Tronci E; Pioli EY; Li Q; Porras G; Björklund A; Carta M
Neurosci Res; 2013 Dec; 77(4):242-6. PubMed ID: 24135129
[TBL] [Abstract][Full Text] [Related]
36. Severity of Dyskinesia and D3R Signaling Changes Induced by L-DOPA Treatment of Hemiparkinsonian Rats Are Features Inherent to the Treated Subjects.
Albarrán-Bravo S; Ávalos-Fuentes JA; Cortés H; Rodriguez-Sánchez M; Leyva-García N; Rangel-Barajas C; Erlij D; Florán B
Biomolecules; 2019 Sep; 9(9):. PubMed ID: 31480516
[TBL] [Abstract][Full Text] [Related]
37. Serotonergic modulation of receptor occupancy in rats treated with L-DOPA after unilateral 6-OHDA lesioning.
Nahimi A; Høltzermann M; Landau AM; Simonsen M; Jakobsen S; Alstrup AK; Vang K; Møller A; Wegener G; Gjedde A; Doudet DJ
J Neurochem; 2012 Mar; 120(5):806-17. PubMed ID: 22117574
[TBL] [Abstract][Full Text] [Related]
38. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
[TBL] [Abstract][Full Text] [Related]
39. Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A receptor blockade plus L-dopa in dopamine-denervated rats.
Carta AR; Pinna A; Cauli O; Morelli M
Synapse; 2002 Jun; 44(3):166-74. PubMed ID: 11954048
[TBL] [Abstract][Full Text] [Related]
40. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
Morin N; Morissette M; Grégoire L; Gomez-Mancilla B; Gasparini F; Di Paolo T
Neuropharmacology; 2013 Oct; 73():216-31. PubMed ID: 23756168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
